(Q37244367)

English

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation

scientific article published on 26 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation (English)

1 reference

Europe PubMed Central

19 August 2017

1 reference

based on heuristic

inferred from title

brain metastasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Esin Oktay

1

1 reference

Europe PubMed Central

19 August 2017

Ozlem Yersal

2

1 reference

Europe PubMed Central

19 August 2017

Nezih Meydan

3

1 reference

Europe PubMed Central

19 August 2017

Mehmet Sağıroğlu

4

1 reference

Europe PubMed Central

19 August 2017

Omer Uyanık

5

1 reference

Europe PubMed Central

19 August 2017

Sabri Barutca

6

1 reference

Europe PubMed Central

19 August 2017

publication date

26 September 2013

1 reference

Europe PubMed Central

19 August 2017

Case Reports in Oncological Medicine

1 reference

Europe PubMed Central

19 August 2017

2013

1 reference

Europe PubMed Central

19 August 2017

234391

1 reference

Europe PubMed Central

19 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

6 September 2017

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

6 September 2017

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

6 September 2017

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

6 September 2017

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

6 September 2017

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

3 September 2018

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

3 September 2018

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

3 September 2018

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3804136

3 September 2018

Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe

1 reference

https://pubmed.ncbi.nlm.nih.gov/24191208

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2013/234391

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37244367&oldid=1799230379"